Sunil Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sunil Kumar has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
- Antonio L. Amelio
Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida
34 shared publications - Christine H. Chung
Moffitt Cancer Center, Tampa, FL
28 shared publications - Kedar Kirtane
Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL
28 shared publications - Gaorav P. Gupta
Lineberger Comprehensive Cancer Center
27 shared publications Alessandro Porrello
23 shared publicationsAlisha R. Coffey
23 shared publications
Latest Publications
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Baseline patient characteristics
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Baseline patient characteristics
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 1: Trial Schema and Timepoints of Sample Collection. Oral gargle samples were collected at weekly intervals from baseline to week 4, then at end of treatment and at 3, 6, and 12 months after treatment. Plasma samples were collected at baseline, week 4, end of treatment, and at 3, 6, 12, 18, and 24 months after treatment. Imaging studies done at week 4 was used to assess %reduction of target tumor volume at week 4.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 1: Trial Schema and Timepoints of Sample Collection. Oral gargle samples were collected at weekly intervals from baseline to week 4, then at end of treatment and at 3, 6, and 12 months after treatment. Plasma samples were collected at baseline, week 4, end of treatment, and at 3, 6, 12, 18, and 24 months after treatment. Imaging studies done at week 4 was used to assess %reduction of target tumor volume at week 4.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 4: Oral Gargle HPV DNA Collected at Weekly Intervals from Weeks 1 to 4 and Their Associations with Reduction of Target Tumor Volume (TTV) at Week 4. A) Comparison of the reduction of TTV at week 4 in patients with versus without week 4 oral gargle cfHPV DNA clearance; B) week 1 oral gargle cfHPV DNA clearance; C) week 2 oral gargle cfHPV DNA clearance; and D) week 3 oral gargle cefHPV DNA clearance. Positive (i.e. >0) numbers represent tumor volume reduction while negative (i.e. <0) numbers represent tumor volume increase. Statistical test represents Mann-Whitney Test between the 2 groups overlaid by the bolded line. The median and upper and lower quartiles are represented in the bar graphs.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 4: Oral Gargle HPV DNA Collected at Weekly Intervals from Weeks 1 to 4 and Their Associations with Reduction of Target Tumor Volume (TTV) at Week 4. A) Comparison of the reduction of TTV at week 4 in patients with versus without week 4 oral gargle cfHPV DNA clearance; B) week 1 oral gargle cfHPV DNA clearance; C) week 2 oral gargle cfHPV DNA clearance; and D) week 3 oral gargle cefHPV DNA clearance. Positive (i.e. >0) numbers represent tumor volume reduction while negative (i.e. <0) numbers represent tumor volume increase. Statistical test represents Mann-Whitney Test between the 2 groups overlaid by the bolded line. The median and upper and lower quartiles are represented in the bar graphs.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 2: Association of Baseline Clinical Characteristics with Plasma and Oral Gargle HPV DNA Status. Bar charts show the comparison of proportions of patients with A) detectable versus undetectable baseline plasma cfHPV DNA or B) detectable versus undetectable baseline oral gargle HPV DNA stratified by key baseline clinical variable groups. P-values represent Fisher’s Exact Tests where p < 0.05 is considered significant.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 2: Association of Baseline Clinical Characteristics with Plasma and Oral Gargle HPV DNA Status. Bar charts show the comparison of proportions of patients with A) detectable versus undetectable baseline plasma cfHPV DNA or B) detectable versus undetectable baseline oral gargle HPV DNA stratified by key baseline clinical variable groups. P-values represent Fisher’s Exact Tests where p < 0.05 is considered significant.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 3: Week 4 Plasma Cell-Free HPV (cfHPV) or Oral Gargle HPV DNA and its Association with Progression-free Survival (PFS). A) Comparison of PFS for patients with versus without week 4 plasma cfHPV DNA clearance. B) Comparison of PFS for patients with versus without week 4 oral gargle cfHPV DNA clearance. Log-rank test represents a comparison between the respective groups.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 3: Week 4 Plasma Cell-Free HPV (cfHPV) or Oral Gargle HPV DNA and its Association with Progression-free Survival (PFS). A) Comparison of PFS for patients with versus without week 4 plasma cfHPV DNA clearance. B) Comparison of PFS for patients with versus without week 4 oral gargle cfHPV DNA clearance. Log-rank test represents a comparison between the respective groups.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Waterfall plot showing the % change of week 4 TTV compared with baseline for all patients who met the inclusion criteria (N = 50). Each legend at the bottom of the waterfall plot show the status of HPV DNA clearance for oral gargle at weekly intervals for weeks 1 to 4 and for plasma at week 4; baseline HPV DNA status by plasma and oral gargle; and the locoregional disease-free survival (LRFS), distant metastatic disease-free survival (DMFS) recurrence, and PFS statuses at 24 months after treatment of individual patients.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Waterfall plot showing the % change of week 4 TTV compared with baseline for all patients who met the inclusion criteria (N = 50). Each legend at the bottom of the waterfall plot show the status of HPV DNA clearance for oral gargle at weekly intervals for weeks 1 to 4 and for plasma at week 4; baseline HPV DNA status by plasma and oral gargle; and the locoregional disease-free survival (LRFS), distant metastatic disease-free survival (DMFS) recurrence, and PFS statuses at 24 months after treatment of individual patients.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Association between baseline cfHPV DNA and PFS. Comparison of PFS for patients with low (
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Association between baseline cfHPV DNA and PFS. Comparison of PFS for patients with low (
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Dynamic biomarkers that guide de-escalation strategies in human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) remain an unmet need. In this study, we evaluated the kinetics of plasma cell-free HPV (cfHPV) DNA and oral gargle HPV DNA during radiotherapy in patients with low-risk HPV-related OPSCC. Data were obtained from a trial evaluating an adaptive model optimizing radiation fractionation in patients with low-risk (T0-2N0-1M0) HPV-related OPSCC undergoing radiotherapy. The primary objective was to determine whether week 4 plasma cfHPV DNA or oral gargle HPV DNA clearance is associated with reduction of target tumor volume (TTV) at week 4. A total of 325 plasma and 334 oral gargle samples from 50 patients with available baseline samples were analyzed. Higher baseline plasma cfHPV DNA was associated with higher nodal staging (P = 0.002), whereas oral gargle HPV DNA was detected more frequently in the tonsil or soft palate than occult or base of tongue primary tumors (P = 0.039). Week 4 plasma but not oral gargle HPV DNA clearance was associated with higher reduction of TTV at week 4 (P = 0.0063). Whereas week 4 plasma and oral gargle HPV DNA clearance was not associated with progression-free survival, a lower baseline plasma cfHPV DNA was associated with superior progression-free survival (P = 0.027). Week 4 plasma cfHPV DNA clearance aligns with reduction in TTV, and future studies are warranted to determine the role of early plasma cfHPV DNA clearance in biomarker-adapted de-escalation strategies.Significance:Our findings may inform appropriate patient selection for low-risk HPV-related OPSCC based on cfHPV DNA in future deintensification studies, aimed at preventing or minimizing treatment-related toxicities in patients who may have lower risk of recurrence.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Dynamic biomarkers that guide de-escalation strategies in human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) remain an unmet need. In this study, we evaluated the kinetics of plasma cell-free HPV (cfHPV) DNA and oral gargle HPV DNA during radiotherapy in patients with low-risk HPV-related OPSCC. Data were obtained from a trial evaluating an adaptive model optimizing radiation fractionation in patients with low-risk (T0-2N0-1M0) HPV-related OPSCC undergoing radiotherapy. The primary objective was to determine whether week 4 plasma cfHPV DNA or oral gargle HPV DNA clearance is associated with reduction of target tumor volume (TTV) at week 4. A total of 325 plasma and 334 oral gargle samples from 50 patients with available baseline samples were analyzed. Higher baseline plasma cfHPV DNA was associated with higher nodal staging (P = 0.002), whereas oral gargle HPV DNA was detected more frequently in the tonsil or soft palate than occult or base of tongue primary tumors (P = 0.039). Week 4 plasma but not oral gargle HPV DNA clearance was associated with higher reduction of TTV at week 4 (P = 0.0063). Whereas week 4 plasma and oral gargle HPV DNA clearance was not associated with progression-free survival, a lower baseline plasma cfHPV DNA was associated with superior progression-free survival (P = 0.027). Week 4 plasma cfHPV DNA clearance aligns with reduction in TTV, and future studies are warranted to determine the role of early plasma cfHPV DNA clearance in biomarker-adapted de-escalation strategies.Significance:Our findings may inform appropriate patient selection for low-risk HPV-related OPSCC based on cfHPV DNA in future deintensification studies, aimed at preventing or minimizing treatment-related toxicities in patients who may have lower risk of recurrence.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Dynamic changes of plasma cfHPV DNA and its association with reduction of TTV at week 4. A, Plasma cfHPV DNA kinetics before, during, and after definitive radiation treatment. Each colored line represents a patient. Colors of lines represent patients who did (red) and did not (blue) have confirmed disease progression at 24 months. B, A box plot showing the % reduction of TTV at week 4 for patients who did or did not achieve plasma cfHPV DNA clearance at week 4. Positive (i.e., >0) numbers represent tumor volume reduction, whereas negative (i.e., <0) numbers represent tumor volume increase. Statistical test represents the Mann–Whitney test between the two groups overlaid by the bolded line. The median and upper and lower quartiles are represented in the bar graphs.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Dynamic changes of plasma cfHPV DNA and its association with reduction of TTV at week 4. A, Plasma cfHPV DNA kinetics before, during, and after definitive radiation treatment. Each colored line represents a patient. Colors of lines represent patients who did (red) and did not (blue) have confirmed disease progression at 24 months. B, A box plot showing the % reduction of TTV at week 4 for patients who did or did not achieve plasma cfHPV DNA clearance at week 4. Positive (i.e., >0) numbers represent tumor volume reduction, whereas negative (i.e., <0) numbers represent tumor volume increase. Statistical test represents the Mann–Whitney test between the two groups overlaid by the bolded line. The median and upper and lower quartiles are represented in the bar graphs.